CDC7 and liver cancer: The sequential release of a senescence inducer (CDC7 inhibitor) and a CD47 inhibitor from the dual‐targeting nanosystem in situ induced senescence and antitumor immune responses to aganist liver cancer and overcome chemoresistance.